Hyocholic Acid (Synonyms: γ-Muricholic Acid) |
| Catalog No.GC40717 |
Hyocholic acid (γ-Muricholic acid) is the major bile acid in pigs and other mammals and is also found in urine samples of patients with cholestasis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 547-75-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Hyocholic acid (γ-Muricholic acid) is the major bile acid in pigs and other mammals and is also found in urine samples of patients with cholestasis[1]. Hyocholic acid promotes intracellular glucagon-like peptide-1 (GLP-1) secretion by activating G protein-coupled bile acid receptor (TGR5) and inhibiting farnesoid X receptor (FXR), thereby improving glucose homeostasis[2]. Hyocholic acid can be used as a novel biomarker for metabolic disorders and can resist type 2 diabetes[3].
In vitro, treatment of STC-1 and NCI-H716 cells with hyocholic acid (25, 50 μM) for 24 h upregulated GLP-1 protein secretion and proglucagon gene transcription in cells [4].
In vivo, oral treatment of diabetic mice with hyocholic acid (100 mg/kg) reduced blood glucose levels, increased fasting insulin levels, and upregulated serum GLP-1 levels through TGR5 and FXR signaling in vivo [4]. Oral treatment of nonalcoholic hepatitis mice with hyocholic acid (10, 100 mg/kg) for 16 weeks alleviated hepatic steatosis induced by a high-fat, high-cholesterol (HFHC) diet, reduced the production of lipid peroxides in a dose-dependent manner, and prevented hepatocyte apoptosis[5].
References:
[1] Lundell K, Wikvall K. Species-specific and age-dependent bile acid composition: aspects on CYP8B and CYP4A subfamilies in bile acid biosynthesis[J]. Current drug metabolism, 2008, 9(4): 323-331.
[2] Jia W, Rajani C, Zheng X, et al. Hyocholic acid and glycemic regulation: Comments on ‘Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism’[J]. Journal of Molecular Cell Biology, 2021, 13(6): 460-462.
[3] Zheng X, Chen T, Zhao A, et al. Hyocholic acid species as novel biomarkers for metabolic disorders[J]. Nature communications, 2021, 12(1): 1487.
[4] Zheng X, Chen T, Jiang R, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[J]. Cell metabolism, 2021, 33(4): 791-803. e7.
[5] Xie Y, Shen F, He Y, et al. Gamma-muricholic acid inhibits nonalcoholic steatohepatitis: Abolishment of steatosis-dependent peroxidative impairment by FXR/SHP/LXRα/FASN signaling[J]. Nutrients, 2023, 15(5): 1255.
| Cell experiment [1]: | |
Cell lines | STC-1 and NCI-H716 cells |
Preparation Method | Cells were treated with different concentrations (5, 25, and 50μM) of Hyocholic Acid with 24h treatment for determination of GLP-1 secretion and proglucagon transcription. |
Reaction Conditions | 5, 25, 50μM; 24h |
Applications | Hyocholic Acid upregulates GLP-1 protein secretion and proglucagon gene transcription in STC-1 and NCI-H716 cells. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | C57BL/6 mice were randomized into the normal control (NC), NASH, NASH+vehicle, NASH+10mg/kg Hyocholic Acid, and NASH+100mg/kg Hyocholic Acid groups, respectively. Except for those in the NC group with a normal diet, all the mice were exposed to the high-fat high-cholesterol(HFHC) diet (2% cholesterol, 10% lard, and 88% normal diet) for 16 weeks. |
Dosage form | 10、100mg/kg; p.o. |
Applications | Hyocholic Acid attenuated rodent liver steatosis induced by the HFHC diet. Hyocholic Acid treatment dose-dependently reduced the production of lipid peroxides. Hyocholic Acid treatment dose-dependently prevented hepatocytes from the apoptotic process. |
References: [1]Zheng X, Chen T, Jiang R, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[J]. Cell metabolism, 2021, 33(4): 791-803. e7. [2]Xie Y, Shen F, He Y, et al. Gamma-muricholic acid inhibits nonalcoholic steatohepatitis: Abolishment of steatosis-dependent peroxidative impairment by FXR/SHP/LXRα/FASN signaling[J]. Nutrients, 2023, 15(5): 1255. | |
| Cas No. | 547-75-1 | SDF | |
| Synonyms | γ-Muricholic Acid | ||
| Chemical Name | (5β)-3α,6α,7α-trihydroxy-cholan-24-oic acid | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| Formula | C24H40O5 | M.Wt | 408.6 |
| Solubility | 30 mg/ml in DMF, 20 mg/ml in DMSO, 20 mg/ml in Ethanol | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4474 mL | 12.2369 mL | 24.4738 mL |
| 5 mM | 0.4895 mL | 2.4474 mL | 4.8948 mL |
| 10 mM | 0.2447 mL | 1.2237 mL | 2.4474 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >97.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *